Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor Journal Article

Authors: Scaltriti, M.; Chandarlapaty, S.; Prudkin, L.; Aura, C.; Jimenez, J.; Angelini, P. D.; Sánchez, G.; Guzman, M.; Parra, J. L.; Ellis, C.; Gagnon, R.; Koehler, M.; Gomez, H.; Geyer, C.; Cameron, D.; Arribas, J.; Rosen, N.; Baselga, J.
Article Title: Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor
Abstract: Purpose: A subgroup of human epidermal growth factor receptor 2 (HER2)-overexpressing breast tumors coexpresses p95HER2, a truncated HER2 receptor that retains a highly functional HER2 kinase domain but lacks the extracellular domain and results in intrinsic trastuzumab resistance. We hypothesized that lapatinib, a HER2 tyrosine kinase inhibitor, would be active in these tumors. We have studied the correlation between p95HER2 expression and response to lapatinib, both in preclinical models and in the clinical setting. Experimental Design: Two different p95HER2 animal models were used for preclinical studies. Expression of p95HER2 was analyzed in HER2-overexpressing breast primary tumors from a firstline lapatinib monotherapy study (EGF20009) and a second-line lapatinib in combination with capecitabine study (EGF100151). p95HER2 expression was correlated with overall response rate (complete + partial response), clinical benefit rate (complete response + partial response + stable disease ≥24 wk), and progression-free survival using logistic regression and Cox proportional hazard models. Results: Lapatinib inhibited tumor growth and the HER2 downstream signaling of p95HER2-expressing tumors. A total of 68 and 156 tumors from studies EGF20009 and EGF100151 were evaluable, respectively, for p95HER2 detection. The percentage of p95HER2-positive patients was 20.5% in the EGF20009 study and 28.5% in the EGF100151 study. In both studies, there was no statistically significant difference in progression-free survival, clinical benefit rate, and overall response rate between p95HER2-positive and p95HER2-negative tumors. Conclusions: Lapatinib as a monotherapy or in combination with capecitabine seems to be equally effective in patients with p95HER2-positive and p95HER2-negative HER2-positive breast tumors. ©2010 AACR.
Keywords: signal transduction; mitogen activated protein kinase; protein kinase b; human tissue; treatment outcome; treatment response; survival analysis; unclassified drug; major clinical study; fluorouracil; cancer combination chemotherapy; drug efficacy; monotherapy; nonhuman; capecitabine; cancer patient; animal cell; mouse; animals; mice; in situ hybridization, fluorescence; progression free survival; multiple cycle treatment; breast cancer; gene expression; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor 2; animal experiment; animal model; randomized controlled trials as topic; receptor, epidermal growth factor; antineoplastic activity; xenograft model antitumor assays; breast neoplasms; phosphatidylinositol 3 kinase; cancer model; mice, inbred balb c; protein kinase inhibitors; cancer inhibition; mice, nude; immunoblotting; receptor, erbb-2; trastuzumab; deoxycytidine; quinazolines; lapatinib; 3t3 cells; mammary neoplasms, experimental; protein p85; protein p95her2
Journal Title: Clinical Cancer Research
Volume: 16
Issue: 9
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2010-05-01
Start Page: 2688
End Page: 2695
Language: English
DOI: 10.1158/1078-0432.ccr-09-3407
PUBMED: 20406840
PROVIDER: scopus
PMCID: PMC3243489
Notes: --- - "Cited By (since 1996): 17" - "Export Date: 20 April 2011" - "CODEN: CCREF" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Neal Rosen
    356 Rosen